MEDA AB is a Swedish pharmaceutical company that concentrates on "marketing and market-adapted product development". Through their purchase of Medpointe, they own the pharmaceutical products of Carter-Wallace, now marketed under the name Wallace Pharmaceuticals.[1][2]
References [link]
- ^ "Carter-Wallace". Encyclopedia of New Jersey. https://books.google.com/books?id=_r9Ni6_u0JEC&pg=PA124&lpg=PA124&dq=%22John+Samuel+Carter%22+wallace&source=bl&ots=9CEVAnCtEP&sig=HOQgMC-iqMNmuU6R0hRv_l1IfwA&hl=en&ei=bP2ATp3YHMnz0gHBo_gP&sa=X&oi=book_result&ct=result&resnum=4&ved=0CEgQ6AEwAw#v=onepage&q=%22John%20Samuel%20Carter%22%20wallace&f=false. Retrieved 2011-09-26. "Wallace Pharmaceuticals became MedPointe's prescription pharmaceuticals division. ..."
- ^ "About Us". Wallace Pharmaceuticals. https://www.wallacepharmaceuticals.com/aboutus.html. Retrieved 2011-09-26. "September 2001 brought the biggest change to the Carter-Wallace business in more than one-hundred years when the pharmaceutical and diagnostics businesses of Carter-Wallace, Inc. was sold to MedPointe Capital Partners, backed by private equity firms The Carlyle Group and The Cypress Group in a cash deal valued at approximately $408 million. In the deal, MedPointe acquired Wallace Laboratories, Carter-Wallace's pharmaceutical arm, and Wampole Laboratories, its diagnostics unit, as well as the rights to the Carter-Wallace name."
https://wn.com/Meda_AB
Podcasts:
PLAYLIST TIME: